Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
In addition to its' established metabolic and cardioprotective effects, glucagon-like peptide-1 (GLP-1) reduces post-infarction heart failure via preferential actions on the extracellular matrix (ECM). Here, we investigated whether the GLP-1 mimetic, exendin-4, modulates cardiac remodelling in experimental diabetes by specifically targeting inflammatory/ECM pathways, which are characteristically dysregulated in this setting. Adult mice were subjected to streptozotocin (STZ) diabetes and infused with exendin-4/insulin/saline from 0 to 4 or 4-12 weeks. Exendin-4 and insulin improved metabolic parameters in diabetic mice after 12 weeks, but only exendin-4 reduced cardiac diastolic dysfunction and interstitial fibrosis in parallel with altered ECM gene expression. Whilst myocardial inflammation was not evident at 12 weeks, CD11b-F4/80(++) macrophage infiltration at 4 weeks was increased and reduced by exendin-4, together with an improved cytokine profile. Notably, media collected from high glucose-treated macrophages induced cardiac fibroblast differentiation, which was prevented by exendin-4, whilst several cytokines/chemokines were differentially expressed/secreted by exendin-4-treated macrophages, some of which were modulated in STZ exendin-4-treated hearts. Our findings suggest that exendin-4 preferentially protects against ECM remodelling and diastolic dysfunction in experimental diabetes via glucose-dependent modulation of paracrine communication between infiltrating macrophages and resident fibroblasts, thereby indicating that cell-specific targeting of GLP-1 signalling may be a viable therapeutic strategy in this setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“and an increase in IL-10 expression within the heart was reported. 66”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“Exendin-4, a GLP-1 analog, showed cardioprotective properties in a diabetic animal model by preventing heart remodeling and diastolic dysfunction.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to these effects, a decline in macrophage infiltration, IL-1β, and IL-6 expression was observed”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144 · cited 1×
“heterogeneous nature of monocyte/macrophage populations, which exhibit remarkable plasticity, allowing them to alter physiological function in response to their microenvironment [29].”
BackgroundMacrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Molecular mechanisms of diabetic cardiomyopathy
Bugger, H., & Abel, E. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3171-6 · Cited by 903
Mouse Models of Diabetic Nephropathy
Brosius, F. C., Alpers, C. E., Bottinger, E. P., Breyer, M. D., Coffman, T. M., Gurley, S. B., Harris, R. C., Kakoki, M., Kretzler, M., Leiter, E. H., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070721 · Cited by 895
Cardiovascular remodelling in coronary artery disease and heart failure
Heusch, G., Libby, P., Gersh, B., Yellon, D., Böhm, M., Lopaschuk, G., & Opie, L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60107-0 · Cited by 734
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638
Heart failure prevalence, incidence, and mortality in the elderly with diabetes
Bertoni, A. G., Hundley, W. G., Massing, M. W., Bonds, D. E., Burke, G. L., & Goff, D. C. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.699 · Cited by 596
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“Notably, exendin-4 was infused from 4 weeks, at a concentration comparable to previous experimental studies [32, 34], once elevated glucose levels had been achieved, to further reflect the likely clinical scenario.”
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
Nikolaidis, L. A., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C., Shen, Y.-T., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000139339.85840.dd · Cited by 514
Timmers, L., Henriques, J. P. S., de Kleijn, D. P. V., DeVries, J. H., Kemperman, H., Steendijk, P., Verlaan, C. W. J., Kerver, M., Piek, J. J., Doevendans, P. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.033 · Cited by 470
Mouse Models of Diabetic Nephropathy
Breyer, M. D., Bo[Combining Diaeresis]ttinger, E., Brosius, F. C., Coffman, T. M., Harris, R. C., Heilig, C. W., & Sharma, K. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080648 · Cited by 467
Movahed, M.-R., Hashemzadeh, M., & Mazen Jamal, M. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.02.050 · Cited by 379
Barouch, L. A., Berkowitz, D. E., Harrison, R. W., O’Donnell, C. P., & Hare, J. M. (2003) · Circulation · doi:10.1161/01.cir.0000083716.82622.fd · Cited by 341
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319 · cited 1×
“Of particular relevance to our study, a GLP-1-producing recombinant adenovirus inhibits adipose tissue macrophage infiltration and inflammation in ob/ob diabetic mice [22].”
BackgroundExenatide Exerts a Potent Antiinflammatory Effect
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284
Matsubara, J., Sugiyama, S., Sugamura, K., Nakamura, T., Fujiwara, Y., Akiyama, E., Kurokawa, H., Nozaki, T., Ohba, K., Konishi, M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.07.053 · Cited by 273
Westermann, D., Rutschow, S., Jäger, S., Linderer, A., Anker, S., Riad, A., Unger, T., Schultheiss, H.-P., Pauschinger, M., & Tschöpe, C. (2007) · Diabetes · doi:10.2337/db06-1163 · Cited by 273
Ma, F., Li, Y., Jia, L., Han, Y., Cheng, J., Li, H., Qi, Y., & Du, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035144 · Cited by 271
Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice
Semeniuk, L. M., Kryski, A. J., & Severson, D. L. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00088.2002 · Cited by 266
Increased Myocardial Oxygen Consumption Reduces Cardiac Efficiency in Diabetic Mice
How, O.-J., Aasum, E., Severson, D. L., Chan, W. Y. A., Essop, M. F., & Larsen, T. S. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1164 · Cited by 248
Collagen remodelling in myocardia of patients with diabetes.
Shimizu, M., Umeda, K., Sugihara, N., Yoshio, H., Ino, H., Takeda, R., Okada, Y., & Nakanishi, I. (1993) · Journal of Clinical Pathology · doi:10.1136/jcp.46.1.32 · Cited by 247
Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin Chemotherapy
Zhao, Y., McLaughlin, D., Robinson, E., Harvey, A. P., Hookham, M. B., Shah, A. M., McDermott, B. J., & Grieve, D. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2664 · Cited by 244
Self-citationHogan, A. E., Gaoatswe, G., Lynch, L., Corrigan, M. A., Woods, C., O’Connell, J., & O’Shea, D. (2014) · Diabetologia · doi:10.1007/s00125-013-3145-0 · Cited by 239
Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
Shiraishi, D., Fujiwara, Y., Komohara, Y., Mizuta, H., & Takeya, M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.086 · Cited by 208
Mechanisms of Cardiac Fibrosis in Inflammatory Heart Disease
Kania, G., Blyszczuk, P., & Eriksson, U. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2010.02.005 · Cited by 189
Poornima, I., Brown, S. B., Bhashyam, S., Parikh, P., Bolukoglu, H., & Shannon, R. P. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.108.766402 · Cited by 182
de Simone, G., Devereux, R. B., Chinali, M., Lee, E. T., Galloway, J. M., Barac, A., Panza, J. A., & Howard, B. V. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283331169 · Cited by 143
Ussher, J. R., Baggio, L. L., Campbell, J. E., Mulvihill, E. E., Kim, M., Kabir, M. G., Cao, X., Baranek, B. M., Stoffers, D. A., Seeley, R. J., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.04.009 · Cited by 139
Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging
Di Bonito, P., Moio, N., Cavuto, L., Covino, G., Murena, E., Scilla, C., Turco, S., Capaldo, B., & Sibilio, G. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01685.x · Cited by 137
Bose, A., Mocanu, M. M., Carr, R. D., & Yellon, D. M. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-6892-4 · Cited by 127
Liu, Q., Anderson, C., Broyde, A., Polizzi, C., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-76 · Cited by 124
Grieve, D. J., Cassidy, R. S., & Green, B. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00376.x · Cited by 121
Self-citationSchilling, J. D., & Mann, D. L. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.007 · Cited by 117
Steven, S., Hausding, M., Kröller-Schön, S., Mader, M., Mikhed, Y., Stamm, P., Zinßius, E., Pfeffer, A., Welschof, P., Agdauletova, S., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0465-x · Cited by 114 · cited 1×
“Notably, in addition to our previous work highlighting macrophage-specific effects of exendin-4 post-MI [34], many basic and clinical studies are broadly supportive of persistent anti-inflammatory actions of GLP-1, including specific reduction of TNF-a, IL-6, TLR-2/4, NF-jb, and MMP-9, which are key drivers of cardiac…”
BackgroundKatare, R. G., Caporali, A., Oikawa, A., Meloni, M., Emanueli, C., & Madeddu, P. (2010) · Circulation: Heart Failure · doi:10.1161/circheartfailure.109.903450 · Cited by 102
Hausenloy, D. J., Whittington, H. J., Wynne, A. M., Begum, S. S., Theodorou, L., Riksen, N. P., Mocanu, M. M., & Yellon, D. M. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-154 · Cited by 102
Robinson, E., Cassidy, R. S., Tate, M., Zhao, Y., Lockhart, S., Calderwood, D., Church, R., McGahon, M. K., Brazil, D. P., McDermott, B. J., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0476-7 · Cited by 67
Self-citationDeNicola, M., Du, J., Wang, Z., Yano, N., Zhang, L., Wang, Y., Qin, G., Zhuang, S., & Zhao, T. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00109.2014 · Cited by 62
Urbina, P., & Singla, D. K. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00367.2014 · Cited by 60
Leptin as an adjunct of insulin therapy in insulin-deficient diabetes
Miyanaga, F., Ogawa, Y., Ebihara, K., Hidaka, S., Tanaka, T., Hayashi, S., Masuzaki, H., & Nakao, K. (2003) · Diabetologia · doi:10.1007/s00125-003-1193-6 · Cited by 57
Moberly, S. P., Mather, K. J., Berwick, Z. C., Owen, M. K., Goodwill, A. G., Casalini, E. D., Hutchins, G. D., Green, M. A., Ng, Y., Considine, R. V., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0365-x · Cited by 51
Lu, H. Y., Huang, C., Shih, C. M., Chang, W. H., Tsai, C.-S., Lin, F., & Shih, C. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121077 · Cited by 47
Macrophages modulate cardiac function in lipotoxic cardiomyopathy
Schilling, J. D., Machkovech, H. M., Kim, A. H. J., Schwedwener, R., & Schaffer, J. E. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00111.2012 · Cited by 46
Keith, M. C. L., Tokita, Y., Tang, X.-L., Ghafghazi, S., Moore, J. B., Hong, K. U., Elmore, J. B., Amraotkar, A. R., Guo, H., Ganzel, B. L., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0503-8 · Cited by 41
Hernández‐Reséndiz, S., Flores, C. P., Santos, S. D. L., Román-Anguiano, N. G., Flores-García, M., de la Peña-Dı́az, A., Flores, P., Fernández-G, J. M., Coral‐Vázquez, R. M., & Zazueta, C. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0464-y · Cited by 40
Wang, Y., Ebermann, L., Sterner‐Kock, A., Wika, S., Schultheiss, H., Dörner, A., & Walther, T. (2009) · Experimental Physiology · doi:10.1113/expphysiol.2008.044800 · Cited by 37
Adult human β‐cell neogenesis?
Demeterco, C., Hao, E., Lee, S., Itkin-Ansari, P., & Levine, F. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01105.x · Cited by 35
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33 · cited 5×
“focused on the cardiovascular actions of glucagon-like peptide-1 (GLP-1), whose established metabolic effects have been clinically exploited for glycemic control in type 2 diabetes [14, 41].”
BackgroundInfluentialSelf-citationAdachi, H., Kondo, T., Koh, G. Y., Nagy, A., Oike, Y., & Araki, E. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.110 · Cited by 27
Insulin-dependent Diabetes Mellitus in Mice Does Not Alter Liver Heparan Sulfate
Bishop, J. R., Foley, E. M., Lawrence, R., & Esko, J. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.112391 · Cited by 20
Cited by
Basic Mechanisms of Diabetic Heart Disease
Ritchie, R. H., & Abel, E. D. (2020) · Circulation Research · doi:10.1161/circresaha.120.315913 · Cited by 708
Mouton, A. J., Li, X., Hall, M. E., & Hall, J. E. (2020) · Circulation Research · doi:10.1161/circresaha.119.312321 · Cited by 546
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
“This was associated with a reduction in macrophage infiltration, lower expression of IL-1b and IL-6, and an increase in IL-10 in the heart (41).”
Background
Metadata
- Authors
- Tate, M., Robinson, E., Green, B. D., McDermott, B. J., & Grieve, D. J.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Grieve, David J.
- Venue
- Basic Research in Cardiology
- Published
- 2015-11-23
- Volume
- 111
- Issue
- 1
- Pages
- 1-1
- ISSN
- 0003-9217 (ISSN-L)
- 0300-8428
- 1435-1803
- PMC
- PMC4656717
- OpenAlex
- W2239026788
- Cited by
- 96
- References
- 52
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 9 · 2023: 3 · 2022: 6 · 2021: 11 · 2020: 15 · 2019: 5 · 2018: 13 · 2017: 15 · 2016: 11
- FWCI
- 9.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Basic Research in Cardiology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion, cc-by)
- Funders
- British Heart Foundation (PG/09/102, FS/11/36/28872)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- exendin-4, glucagon-like peptide-1, cardiac remodeling, streptozotocin-induced diabetes, macrophage infiltration, extracellular matrix remodeling, myocardial fibrosis, diastolic dysfunction, cardiac fibroblast differentiation, paracrine signaling, insulin, heart failure
- MeSH terms
- Exenatide, Animals, Diabetes Mellitus, Experimental, Extracellular Matrix, Fibroblasts, Flow Cytometry, Heart, Hypoglycemic Agents, Immunohistochemistry, Macrophages, Male, Mice, Inbred C57BL, Peptides, Venoms, Polymerase Chain Reaction, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.